Jobs Board
Log In Become a Member
Knowledge Exchange UK
Jobs Board
Log In Become a Member
  • Home
  • Membership
    • hidden – do not delete
  • Learn & Develop
    • hidden – do not delete
  • Events
    • hidden – do not delete
  • News
    • Member News
  • Resources
    • hidden – do not delete
  • Home
  • Membership
    • Why Join Us?
    • Become a member
    • Members Directory
  • Learn & Develop
    • Book a course
    • In-House Training
  • Events
    • Conference
    • KE Awards
    • Directors’ Forum
    • Online Events
  • Resources
    • Blog
    • Reports
    • Webinars
  • About
    • About Us
    • Brand Guidelines
    • Work with us
    • What is Knowledge Exchange?
  • KE Concordat
    • About
    • The 8 Guiding Principals
  • Jobs Board
  • Social Ventures and SHAPE
Log In Become a Member
Membership
Join our community of knowledge exchange professionals and access exclusive resources, events, and networking opportunities.
Become a member
Be part of our community
Why Join Us?
Become a member
Renew your membership
Members Directory
Member Events
Online Community
Communities & Groups
Resources
Browse our resources for blogs, news articles and all the information, advice and support you need in knowledge exchange and commercialisation.
View all resources
Media
News Articles
Blogs
Webinars
Reports
Topic Hubs
KE Concordat
KE Matters
AI
Government
Funding
Inclusion and diversity
Knowledge Exchange
Technology Transfer
Intellectual Property
SHAPE
Spinouts
Sustainability
Events
Join our networking events, including annual conference, KE Awards, Directors' Forum, and a variety of member-only gatherings.
View our events
Conference
Overview
Abstracts
Sponsorship
KE Awards
Attend
Finalists
Supporters & Sponsors
Judging Panel
Events
All Events
Directors' Forum
KE Matters
Learn & Develop
Continue your professional development with our training courses, workshops, and tailored in-house training designed to enhance your skills and knowledge.
Find out more
Our Courses
Fundamentals of Technology Transfer
Research Contracts
Practical Business Development
Spinout Creation
Software Commercialisation
Negotiation for Knowledge Exchange Professionals
Commercialisation in Healthcare
Establishing and Growing a Successful TTO
Practical Licensing
Developing Strategic Partnerships
New to Knowledge Exchange Programme
Leadership in Knowledge Exchange
Knowledge Exchange for Academics
Fundamentals of IP
CPD Opportunities
Book onto a training course
In-House Training
Mentoring
Become a volunteer
Apply for RTTP

Contact Us

+44 (0)1223 776130
info@ke.org.uk

St John's Innovation Centre
Cowley Rd,
Milton,
Cambridge,
CB4 0WS

Follow Us

Home > New drug halves hearing loss in children following cancer treatment

Giving the drug sodium thiosulphate after chemotherapy reduces hearing loss in children treated for liver cancer, according to findings published in the New England Journal of Medicine today (Wednesday).

Results from the Cancer Research UK funded SIOPEL-6 clinical trial show that giving sodium thiosulphate (STS), after a type of chemotherapy called cisplatin, reduces hearing loss by nearly 50% in children treated for hepatoblastoma*, a childhood liver cancer.

This is a major step forward in minimising the number of children left with debilitating and long term side effects after being treated for cancer.

Dr Penelope Brock, trial lead and paediatric consultant at Great Ormond Street Hospital, said: “We’re lucky to have such an effective treatment for this type of liver cancer. But like many cancer treatments, there can also be long term side effects. For children treated with cisplatin alone, a huge proportion are left with permanent hearing loss, which can be utterly debilitating. Even mild hearing loss can severely impact a child’s future development. Key consonants are heard at high frequencies like ‘s,’ ‘h,’ and ‘f’, and their loss can be particularly difficult for children who haven’t yet developed speech.

“This treatment combination could help ensure that parents aren’t faced with an upsetting scenario where successful cancer treatment comes at the cost of their child’s hearing.”

109 children took part in the trial, which was led by researchers at Great Ormond Street Hospital, and had either cisplatin alone or cisplatin followed by STS 6 hours later. While 63% of children given cisplatin alone suffered a degree of hearing loss, this was only the case for one third (33%) of children also given STS, meaning their risk of this side effect was reduced by 48%.**

Importantly, there was no difference in overall survival or incidence of cancer returning, meaning the treatment was just as effective if children were given STS. 

Professor Pam Kearns, Cancer Research UK’s expert on children’s cancers at the University of Birmingham, said: “No child should have to suffer a disability as a result of their cancer treatment. Hearing is precious and we’re delighted to see that we can safeguard the future development of more children, without compromising the chance of curing their cancer.”

Cisplatin*** is a very effective treatment for many cancers including hepatoblastoma, for which survival has improved dramatically. However, around two thirds of children treated with this drug are left with some hearing loss. This is because while cisplatin is rapidly removed from the body following treatment, it is retained in and damages the cochlea, the portion of the inner ear responsible for hearing.

Preclinical and clinical research, by a team led by Dr Ed Neuwelt at Oregon Health and Science University, had previously shown that STS could prevent hearing loss caused by cisplatin. Scientists then determined how to delay when STS was given to patients to avoid any interference with cisplatin’s effect on their tumour. 

In light of these latest results, STS could become part of a new standard of care for treating hepatoblastoma, and researchers are also looking at whether it could work for other children’s cancers where cisplatin is used as part of treatment. The next step is to get marketing authorisation from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA). It has already received a breakthrough therapy designation by the FDA and will be filed under a Paediatric Use Marketing Application in the EU.

Ollie Simpkin, 12, from Islington, was diagnosed with hepatoblastoma when he was five-months-old.  Ollie’s mum Philly Simpkin, said: “After eight rounds of chemotherapy and surgery at GOSH, the great news is that Ollie is now cancer free. While Cisplatin was very effective in shrinking Ollie’s tumour, it is a very strong drug which can lead to serious side effects including hearing loss. We are very thankful that this was kept to a minimum for Ollie but he has still lost the top end of his hearing. This means he struggles to hear in big crowds and has to sit at the front of the class. He really wants to learn to play the drums, but we can’t risk the damage getting any worse.

“When Ollie was going through treatment, STS hadn’t been developed yet, but it’s fantastic that this new treatment could prevent other children from experiencing similar damage that can have such a big impact on their life.”

The SIOPEL-6 trial recruited patients from 52 centres in 12 countries. In the UK, the trial coordination was funded by Cancer Research UK. The STS drug was provided free of charge by Fennec Pharmaceuticals.****

“International trials like this are crucial to help us improve treatments for children,” added Professor Kearns. “The UK is a major contributor to clinical trials research across Europe and this is something we hope will continue. Researchers and patients need certainty on clinical trials both during and beyond the Brexit transition period.”

Knowledge Exchange Logo
Quick Links
  • About Us
  • What is KE?
  • KE Connect
  • Jobs Board
  • Contact
Membership
  • Why join us?
  • Become a member
  • Members Directory
  • Member events
CPD
  • Training Courses
  • In-House Training
  • Workshops
  • Become a Volunteer
  • Course Trainers
  • Moodle LMS
Events
  • Conference
  • KE Awards
  • Directors’ Forum
  • Events
Legal
  • Terms & Conditions
  • Events T & C
  • Privacy Policy
  • Cookies
Follow Us
© Knowledge Exchange UK 2026 | Co. Registration no. 05090806 | VAT no. GB292701793
Membership Website Design | Douglass Digital

Subscribe to our Newsletters

Sign up to the Knowledge Exchange UK newsletter for for news, training, jobs and event updates.

First Name:*
Last Name:*
Email:*
Organisation:*
Job Title:*